P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (NCT04960579)

🧪 Interventions in This Study

• P-BCMA-ALLO1 CAR-T cells (BIOLOGICAL)
• Rimiducid (DRUG)
• Methotrexate (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Must have signed written, informed consent.
2. Males or females, ≥18 years of age.
3. Must have a confirmed diagnosis of active MM.
4. Must have measurable MM.
5. Must have relapsed / refractory MM, having received treatment with a proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy.
6. Must be willing to practice birth control from the time of Screening and throughout the first year of the study after P-BCMA-ALLO1 administration.
7. Must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within 3 days prior to initiating the lymphodepletion therapy regimen (females of childbearing potential).
8. Must be at least 90 days since autologous stem cell transplant, if performed.
9. Must have adequate vital organ function within pre-determined parameters.
10. Must have recovered from toxicities due to prior therapies.
11. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (23 Sites)

• City of Hope — Goodyear, Arizona
• University of California San Diego — San Diego, California
• University of California San Francisco — San Francisco, California
• Emory University — Atlanta, Georgia
• Blood Marrow and Transplant Group of Georgia — Atlanta, Georgia
• City of Hope — Chicago, Illinois
• Advocate Aurora Health — Park Ridge, Illinois
• University of Iowa — Iowa City, Iowa
• University of Kansas Medical Center — Kansas City, Kansas
• University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
• Wayne State - Karmanos Cancer Institute — Detroit, Michigan
• Hackensack Meridian Health — Hackensack, New Jersey
• Roswell Park Comprehensive Cancer Center — Buffalo, New York
• Mount Sinai — New York, New York
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• University of Cincinnati — Cincinnati, Ohio
• Cleveland Clinic — Cleveland, Ohio
• University of Oklahoma, Health Sciences Center — Oklahoma City, Oklahoma
• University of Pennsylvania — Philadelphia, Pennsylvania
• Vanderbilt University Medical Center — Nashville, Tennessee
• Sarah Cannon Research Institute - St. David's South Austin Medical Center — Austin, Texas
• Houston Methodist Research Institute — Houston, Texas
• Sarah Cannon Research Institute - Methodist Healthcare — San Antonio, Texas

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
• 💵 Compensation indicated: After enrollment, subjects may receive a lymphodepletion therapy regimen before administration of allogeneic CAR-T cells, administered as a single or multiple dose(s).

More studies in Multiple Myeloma

• Registry for Adults With Plasma Cell Disorders (PCD's) — Chapel Hill, North Carolina
• A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma — Mobile, Alabama
• A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events — San Francisco, California
• A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients — Goodyear, Arizona
• Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) — Miami, Florida
• Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma — La Crosse, Wisconsin

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.